Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.

[1]  S. Cannistra,et al.  Advances in the Management of Platinum-Sensitive Relapsed Ovarian Cancer. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  I. Vergote,et al.  ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  P. DiSilvestro,et al.  Maintenance treatment of recurrent ovarian cancer: Is it ready for prime time? , 2018, Cancer treatment reviews.

[4]  James X. Sun,et al.  Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.

[5]  Val Gebski,et al.  Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. , 2017, The Lancet. Oncology.

[6]  D. Mukamel,et al.  Variations in patient preferences over side effects of treatments for ovarian cancer: Baseline results of a randomized controlled clinical trial , 2017 .

[7]  M. Morgan,et al.  Patient and physician expectations and communication regarding ovarian cancer prognosis , 2017 .

[8]  R. Ashfaq,et al.  Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. , 2017, The Lancet. Oncology.

[9]  A. Okamoto,et al.  Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Recommendations on incorporating patient-reported outcomes in clinical trials in epithelial ovarian cancer. , 2017, European journal of cancer.

[10]  I. Vergote,et al.  What are the expectations and preferences of patients with ovarian cancer to a maintenance therapy? A NOGGO/GCIG/ENGOT-ov22 survey (Expression IV) in 2101 patients. , 2017 .

[11]  A. Reuss,et al.  Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  Ignace Vergote,et al.  Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. , 2016, The New England journal of medicine.

[13]  K. Gelmon,et al.  Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  M. Parmar,et al.  Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial , 2016, The Lancet.

[15]  Ayala Hubert,et al.  Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. , 2016, Gynecologic oncology.

[16]  A. Oronsky,et al.  Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man—PFS2: A Measure of Therapeutic Action-At-A-Distance , 2015, Neoplasia.

[17]  A. Oza,et al.  Intermediate clinical endpoints: A bridge between progression‐free survival and overall survival in ovarian cancer trials , 2015, Cancer.

[18]  Ayala Hubert,et al.  Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M. Markman.  Maintenance chemotherapy in the management of epithelial ovarian cancer , 2015, Cancer and Metastasis Reviews.

[20]  D. Matei,et al.  Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial , 2014 .

[21]  D. Matei,et al.  Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. , 2014, The Lancet. Oncology.

[22]  B. Monk,et al.  Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper. , 2014, Gynecologic oncology.

[23]  Manash S. Chatterjee,et al.  The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. , 2013, The Lancet. Oncology.

[24]  S. Loibl,et al.  The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  D. Matei,et al.  Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. , 2012, The New England journal of medicine.

[26]  J. Weigelt,et al.  Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors , 2012, Nature Biotechnology.

[27]  J. Yi,et al.  OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  N. Curtin,et al.  Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial , 2007, Molecular Cancer Therapeutics.

[29]  Evaluation of anticancer medicinal products in man. CPMP Working Party on Efficacy of Medicinal Products. , 1990, Pharmacology & toxicology.